Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial
Por:
Castillon J, Plana M, Castelo B, Iglesias L, Hernando J, Tur R, Baste N, Carmona-Bayonas A, Ruiz S, Trigo J, Lorenzo-Lorenzo I, Grande E, Lorente D, Ugidos L, Marquina G, Garcia-Alvarez A, Taberna M, Villamayor J, Molina-Cerrillo J, Alonso-Gordoa T
Publicada:
1 sep 2022
Ahead of Print:
1 sep 2022
Resumen:
|